Report Id: SNS/HC/2586 | July 2022 | Region: Global | 129 Pages
Report Scope & Overview:
The Overactive Bladder Treatment Market Size was valued at USD 3.63 billion in 2022 and is expected to reach USD 4.89 billion by 2030, and grow at a CAGR of 3.8% over the forecast period 2023-2030.
Overactive bladder, commonly known as OAB, is characterised by a frequent and unexpected need to urinate that can be difficult to manage. Overactive bladder occurs when bladder muscles contract reflexively even when the volume of urine in the bladder is low. These involuntary contractions cause a strong desire to urinate. Many times during the day and night, one may feel the need to pass urine, and one may also experience unintentional urine loss (urgency incontinence). The symptoms include a strong urge to urinate that is difficult to control; unintentional loss of urine immediately following an urgent need to urinate (urgency incontinence); urinating often, usually eight or more times per day; and waking up more than two times per night to urinate.
Overactive bladder treatment refers to the various treatments used to treat the abrupt, involuntary contraction of the muscle in the urinary bladder wall. Overactive bladder treatment encompasses a number of treatments, ranging from medication to behavioural adjustments, as well as a combination of the two. The global Overactive Bladder Treatment Market is predicted to be driven by diseases such as chronic kidney disease (CKD) and diabetes, as well as an increase in the elderly population and research and development initiatives.
Rising R&D investments and the introduction of new medicines in the next years
Rapidly ageing population, resulting in an increase in the incidence of diseases characterised by OAB
Urinary incontinence is becoming more common among women and the elderly.
Drug recalls for OAB treatment may impede market growth in the next years.
Novel medicines, resilient pipelines, and drug patent cliffs
OAB social stigma and lack of knowledge
IMPACT OF COVID-19:
Pharmaceutical and biotech businesses, as well as governments worldwide, are collaborating to tackle the COVID-19 outbreak. This is accomplished through assisting in the creation of vaccines in order to meet the challenges of the pharmaceutical supply chain. In addition, there are around 115 vaccine candidates and another 155 compounds in the R&D pipeline. Furthermore, routinely used medications such as hydroxychloroquine have shown a significant increase in demand for COVID-19 control. As many wealthy countries run out of the medicine, there is a spike in demand, which has created enormous prospects for makers of COVID-19 management drugs. As a result of the demand for COVID-19 vaccines and treatment medications, the pharmaceutical and biotechnology industries are expected to increase significantly in the next years.
The anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments segments of the overactive bladder therapy market. Mirabegron had a dominant market share in 2021, owing to advantages such as fewer side effects and a lower risk of dementia. Because of growing usage and investment by market participants in the launch of novel SNM & PTNS devices, the neuromodulation category is expected to rise at a considerable CAGR.
The overactive bladder treatment market is divided into idiopathic and neurogenic overactive bladder syndromes. Because of the increased prevalence of idiopathic overactive bladder diseases, the idiopathic overactive bladder syndrome category accounted for a bigger market share. Additionally, greater use of SNM treatment for individuals with idiopathic overactive bladder is expected to contribute to segmental growth.
Pharmacotherapy divides the market into Anticholinergics, Neurostimulation, Botox, and Mirabegron. Anticholinergics held the biggest market share in 2021, with Mirabegron accounting for the second-largest market value. Botox, on the other hand, is expected to rise at the fastest rate. One of the first lines of medical treatment for overactive bladder is anticholinergics (OAB). Anticholinergic medicines work by inhibiting the actions of the neurotransmitter acetylcholine and aid in the treatment of a wide range of conditions related with parasympathetic nervous system activation, resulting in reduced muscle spasms in the bladder.
Astellas Pharma, Inc., Mylan N.V., Endo International plc, Hisamitsu Pharmaceutical Co., Inc., Teva Pharmaceutical Industries Limited, Allergan, Plc, Sanofi, Aurobindo Pharma Limited, Pfizer, Inc., Medtronic plc,
by Disease Type
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa account for the majority of the overactive bladder therapy market. North America had the largest proportion, followed by Europe. The region's dominance is due to a number of causes, including an increase in the number of individuals with overactive bladder in the United States, as well as advantageous payment regulations for treatment alternatives. Furthermore, the inclination of market participants, together with ANDA and FDA approval for various treatments, is driving market expansion in the region.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 3.63 Billion|
|Market Size by 2030||US$ 4.89 Billion|
|CAGR||CAGR of 3.8% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• by Disease Type (Idopathic OAB and Neurogenic OAB)
• by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron)
• by Pharmacotherapy (Fesoterodine, Tolterodine, Trospium, Anticholinergics, Solifenacin, Oxybutynin, Darifenacin)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Astellas Pharma, Inc., Mylan N.V., Endo International plc, Hisamitsu Pharmaceutical Co., Inc., Teva Pharmaceutical Industries Limited, Allergan, Plc, Sanofi, Aurobindo Pharma Limited, Pfizer, Inc., Medtronic plc.|
|Key Drivers||• Rising R&D investments and the introduction of new medicines in the next years.
• Rapidly ageing population, resulting in an increase in the incidence of diseases characterised by OAB.
|RESTRAINTS||• Urinary incontinence is becoming more common among women and the elderly.|
Frequently Asked Questions (FAQ) :
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
126.96.36.199 United Kingdom
188.8.131.52 South Korea
184.108.40.206 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.Overactive bladder treatment Market , by Type
8.5 Other Treatments.
9.Overactive bladder treatment Market , by Disease Type
9.1 Idiopathic Overactive Bladder
9.2 Neurogenic Overactive Bladder
10.Overactive bladder treatment Market , by Pharmacotherapy
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 Astellas Pharma, Inc.
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Mylan N.V.
12.3 Endo International plc
12.4 Hisamitsu Pharmaceutical Co., Inc.
12.5 Teva Pharmaceutical Industries Limited
12.6 Allergan, Plc
12.8 Aurobindo Pharma Limited
12.9 Pfizer, Inc.
12.10 Medtronic plc
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.